{"DataElement":{"publicId":"3528216","version":"1","preferredName":"Disease or Disorder Grouping Factor Type","preferredDefinition":"A factor, related to the participant's disease or disorder, whose levels separate the sampling units into groups whereby no subject is exposed to more than one level of the factor.","longName":"SARCOMAGRPFACTOR","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"3523213","version":"1","preferredName":"Disease or Disorder Grouping Factor","preferredDefinition":"A factor, related to the participant's disease or disorder, whose levels separate the sampling units into groups whereby no subject is exposed to more than one level of the factor.","longName":"2404658v1.0:3015337v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3015337","version":"1","preferredName":"Grouping Factor","preferredDefinition":"A factor whose levels separate the sampling units into groups whereby no subject is exposed to more than one level of the factor.","longName":"C61039","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grouping Factor","conceptCode":"C61039","definition":"A factor whose levels separate the sampling units into groups whereby no subject is exposed to more than one level of the factor.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"804D27D9-244E-EF36-E040-BB89AD430BD6","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"ONEDATA","dateModified":"2010-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C494C4DE-9435-E039-E040-BB89AD435824","latestVersionIndicator":"Yes","beginDate":"2012-07-11","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3528212","version":"1","preferredName":"Grouping Factor Type","preferredDefinition":"A type of factor whose levels separate the sampling units into groups whereby no subject is exposed to more than one level of the factor.","longName":"3528212v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cohort 5: Other sarcomas","valueDescription":"Other sarcomas","ValueMeaning":{"publicId":"3528213","version":"1","preferredName":"Other sarcomas","longName":"3528213","preferredDefinition":"Other sarcomas","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4F9FC42-6235-B562-E040-BB89AD437E82","latestVersionIndicator":"Yes","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F9FC42-624E-B562-E040-BB89AD437E82","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"ONEDATA","dateModified":"2012-07-16","deletedIndicator":"No"},{"value":"Cohort 4: Malignant peripheral nerve sheath tumor","valueDescription":"Malignant peripheral nerve sheath tumor","ValueMeaning":{"publicId":"2568830","version":"1","preferredName":"Malignant peripheral nerve sheath tumor","longName":"2568830","preferredDefinition":"Malignant peripheral nerve sheath tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F9FC42-6262-B562-E040-BB89AD437E82","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"ONEDATA","dateModified":"2012-07-16","deletedIndicator":"No"},{"value":"Cohort 3: Undifferentiated sarcoma","valueDescription":"Undifferentiated sarcoma (including pleiomorphic undifferentiated sarcoma, formerly known as malignant fibrous histiocytoma, and myxofibrosarcoma)","ValueMeaning":{"publicId":"3528214","version":"1","preferredName":"Undifferentiated sarcoma (including pleiomorphic undifferentiated sarcoma, formerly known as malignant fibrous histiocytoma, and myxofibrosarcoma)","longName":"3528214","preferredDefinition":"Undifferentiated sarcoma (including pleiomorphic undifferentiated sarcoma, formerly known as malignant fibrous histiocytoma, and myxofibrosarcoma)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4F9FC42-626C-B562-E040-BB89AD437E82","latestVersionIndicator":"Yes","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F9FC42-6285-B562-E040-BB89AD437E82","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"ONEDATA","dateModified":"2012-07-16","deletedIndicator":"No"},{"value":"Cohort 2: Leiomyosarcoma (non-uterine)","valueDescription":"Leiomyosarcoma (non-uterine)","ValueMeaning":{"publicId":"3528215","version":"1","preferredName":"Leiomyosarcoma (non-uterine)","longName":"3528215","preferredDefinition":"Leiomyosarcoma (non-uterine)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4F9FC42-628F-B562-E040-BB89AD437E82","latestVersionIndicator":"Yes","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F9FC42-62A8-B562-E040-BB89AD437E82","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"ONEDATA","dateModified":"2012-07-16","deletedIndicator":"No"},{"value":"Cohort 1: Liposarcoma","valueDescription":"Liposarcoma","ValueMeaning":{"publicId":"3179354","version":"1","preferredName":"Liposarcoma","longName":"3179354","preferredDefinition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposarcoma","conceptCode":"C3194","definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-84F7-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F9FC42-62BC-B562-E040-BB89AD437E82","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"ONEDATA","dateModified":"2012-07-16","deletedIndicator":"No"},{"value":"GIST","valueDescription":"Gastrointestinal Stromal Tumor","ValueMeaning":{"publicId":"3179352","version":"1","preferredName":"Gastrointestinal Stromal Tumor","longName":"3179352","preferredDefinition":"GIST. A type of tumor that usually begins in cells in the wall of the gastrointestinal tract.  It can be benign or malignant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastrointestinal Stromal Tumor","conceptCode":"C3868","definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-84AF-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"528E9AF2-6789-6091-E053-F662850AAB52","beginDate":"2017-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-22","modifiedBy":"ONEDATA","dateModified":"2017-06-22","deletedIndicator":"No"},{"value":"UPS/MFH","valueDescription":"Includes undifferentiated pleomorphic sarcoma and malignant fibrous histiosarcoma","ValueMeaning":{"publicId":"5880692","version":"1","preferredName":"Includes undifferentiated pleomorphic sarcoma and malignant fibrous histiosarcoma","longName":"5880692","preferredDefinition":"Includes undifferentiated pleomorphic sarcoma and malignant fibrous histiosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"528E9AF2-6794-6091-E053-F662850AAB52","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"528E9AF2-67AD-6091-E053-F662850AAB52","beginDate":"2017-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-22","modifiedBy":"ONEDATA","dateModified":"2017-06-22","deletedIndicator":"No"},{"value":"Cohort 2: Relapsed or refractory Ph-negative, CD22-positive, B-cell ALL patients","valueDescription":"Cohort Study Two Relapse Or Refractory Philadelphia Chromosome Negative CD22 Positive B-Lymphocyte Acute Lymphoblastic Leukemia Patient","ValueMeaning":{"publicId":"6343898","version":"1","preferredName":"Cohort Study Two Relapse Or Refractory Philadelphia Chromosome Negative CD22 Positive B-Lymphocyte Acute Lymphoblastic Leukemia Patient","longName":"6343898","preferredDefinition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: The return of signs and symptoms of cancer after a period of improvement.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Not responding to treatment.: Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has not been detected in a sample.: Indicates that CD22 expression has been detected in a sample.: Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.: Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.: A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Two","conceptCode":"C66833","definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"7"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Philadelphia Chromosome Negative","conceptCode":"C128844","definition":"Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has not been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"CD22 Positive","conceptCode":"C131066","definition":"Indicates that CD22 expression has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FC82A71-B465-14F0-E053-F662850A84CC","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FC82A71-B47E-14F0-E053-F662850A84CC","beginDate":"2018-06-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","deletedIndicator":"No"},{"value":"Cohort 1: Untreated Ph-negative, CD22-positive, B-cell ALL in transplant-ineligible older patients","valueDescription":"Cohort Study One Negation Treat Philadelphia Chromosome Negative CD22 Positive B-Lymphocyte Acute Lymphoblastic Leukemia Graft Ineligibility Old Patient","ValueMeaning":{"publicId":"6343899","version":"1","preferredName":"Cohort Study One Negation Treat Philadelphia Chromosome Negative CD22 Positive B-Lymphocyte Acute Lymphoblastic Leukemia Graft Ineligibility Old Patient","longName":"6343899","preferredDefinition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).: The smallest natural number and quantity it denotes: a single entity, unit, or object.: An operation in which a term denies or inverts the meaning of another term or construction.: Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.: Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has not been detected in a sample.: Indicates that CD22 expression has been detected in a sample.: Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.: Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.: Tissue or organ transplanted from a donor to a recipient.: The state or quality of being disqualified by law, rule, or provision.: Not new, of an earlier time.: A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"One","conceptCode":"C66832","definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Treat","conceptCode":"C70742","definition":"Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Philadelphia Chromosome Negative","conceptCode":"C128844","definition":"Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has not been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"CD22 Positive","conceptCode":"C131066","definition":"Indicates that CD22 expression has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Graft","conceptCode":"C12981","definition":"Tissue or organ transplanted from a donor to a recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Ineligibility","conceptCode":"C40412","definition":"The state or quality of being disqualified by law, rule, or provision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Old","conceptCode":"C65010","definition":"Not new, of an earlier time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FC82A71-B495-14F0-E053-F662850A84CC","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FC82A71-B4AE-14F0-E053-F662850A84CC","beginDate":"2018-06-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","deletedIndicator":"No"},{"value":"Cohort 3: Untreated Ph-positive, CD22-positive, B-cell ALL older patients","valueDescription":null,"ValueMeaning":{"publicId":"13320166","version":"1","preferredName":"Cohort 3: Untreated Ph-positive, CD22-positive, B-cell ALL older patients","longName":"13320166v1.00","preferredDefinition":"Cohort 3: Untreated Ph-positive, CD22-positive, B-cell ALL older patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F89EE4C7-9ACA-5183-E053-731AD00A712C","latestVersionIndicator":"Yes","beginDate":"2023-04-05","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-04-05","modifiedBy":"ZHWENDY","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F89EE4C7-9ACB-5183-E053-731AD00A712C","beginDate":"2023-04-05","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-04-05","modifiedBy":"ZHWENDY","dateModified":"2023-04-05","deletedIndicator":"No"},{"value":"C1: Safety Run-in Phase: People who have not had a prior PARP-inhibitor for metastatic HER2 negative breast cancer","valueDescription":null,"ValueMeaning":{"publicId":"13369634","version":"1","preferredName":"C1: Safety Run-in Phase: People who have not had a prior PARP-inhibitor for metastatic HER2 negative breast cancer","longName":"13369634v1.00","preferredDefinition":"C1: Safety Run-in Phase: People who have not had a prior PARP-inhibitor for metastatic HER2 negative breast cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F99EA56F-C7AC-5D7D-E053-731AD00AB706","latestVersionIndicator":"Yes","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F99EA56F-C7AF-5D7D-E053-731AD00AB706","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"},{"value":"C2: People who have not had a prior PARP-inhibitor for metastatic HER2 negative breast cancer","valueDescription":null,"ValueMeaning":{"publicId":"13369635","version":"1","preferredName":"C2: People who have not had a prior PARP-inhibitor for metastatic HER2 negative breast cancer","longName":"13369635v1.00","preferredDefinition":"C2: People who have not had a prior PARP-inhibitor for metastatic HER2 negative breast cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F99EA56F-C7AD-5D7D-E053-731AD00AB706","latestVersionIndicator":"Yes","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F99EA56F-C7B0-5D7D-E053-731AD00AB706","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"},{"value":"C3: People who are PARP-inhibitor resistant who have metastatic HER2 negative breast cancer","valueDescription":null,"ValueMeaning":{"publicId":"13369636","version":"1","preferredName":"C3: People who are PARP-inhibitor resistant who have metastatic HER2 negative breast cancer","longName":"13369636v1.00","preferredDefinition":"C3: People who are PARP-inhibitor resistant who have metastatic HER2 negative breast cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F99EA56F-C7AE-5D7D-E053-731AD00AB706","latestVersionIndicator":"Yes","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F99EA56F-C7B1-5D7D-E053-731AD00AB706","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4F9FC42-6220-B562-E040-BB89AD437E82","latestVersionIndicator":"Yes","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"GDEEN","dateModified":"2023-04-18","changeDescription":"Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"SARCOMAGRPFACTOR","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Cohort","type":"Preferred Question Text","description":"Cohort","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Enrollment group","url":null,"context":"Alliance"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4F9FC42-62C6-B562-E040-BB89AD437E82","latestVersionIndicator":"Yes","beginDate":"2012-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-07-16","modifiedBy":"MORENOC","dateModified":"2017-06-22","changeDescription":" Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}